Kopran Limited

NSE KOPRAN.NS

Kopran Limited Price to Earnings Ratio (P/E) on January 14, 2025: 18.07

Kopran Limited Price to Earnings Ratio (P/E) is 18.07 on January 14, 2025, a -59.76% change year over year. Price to earnings ratio compares the stock price to earnings per share; higher P/E suggests expectations for future earnings growth.

Kopran Limited 52-week high Price to Earnings Ratio (P/E) is 50.79 on February 07, 2024, which is 181.03% above the current Price to Earnings Ratio (P/E).
Kopran Limited 52-week low Price to Earnings Ratio (P/E) is 17.37 on January 13, 2025, which is -3.90% below the current Price to Earnings Ratio (P/E).
Kopran Limited average Price to Earnings Ratio (P/E) for the last 52 weeks is 29.03.

Key data

Date	Price to Earnings Ratio (P/E)	Price to Sales Ratio (P/S)	Price to Book Ratio (P/B)	Dividend Yield

NSE: KOPRAN.NS

Kopran Limited

CEO	Mr. Surendra Shrikrishna Somani B.Com.
IPO Date	July 1, 2002
Location	India
Headquarters	Parijat House
Employees	842
Sector	Health Care
Industries Pharmaceuticals

Description

Kopran Limited, an integrated pharmaceutical company, manufactures and sells active pharmaceutical ingredients and finished dosage forms in India and internationally. The company offers its products in various dosage forms, including tablets, capsules, dry powder, suspension, and injectables. It also provides active pharmaceutical ingredients in the categories of macrolide, antibacterial, anticonvulsant, anti-hypertensive, anti-helmentics, anti-histamine, anti-acne, anti-infective, urological, anti-thrombotic, antidiabetic, pain management, gastroenterology, and cardiovascular. The company was incorporated in 1958 and is headquartered in Mumbai, India.

Key trends

Past 5 years